CClinicalTrials.gg
Sign In
Not yet recruitingNCT06715189Updated Dec 4, 2024

Correlation Between Serum Adiponectin And Resistin Levels And Degree of Hepatic Fibrosis in MASlD With type2 Diabetes Mellitus

An observational study in Hepatic Fibrosis, sponsored by Sohag University. Not yet recruiting. Open to participants aged 30 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-12-04.

Sponsored by Sohag University · Observational

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as not yet recruiting.
Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
80
Ages
30 Years to 65 Years
Sex
All
01

Study summary

Metabolic dysfunction asociated steatotic liver disease prevalence is 25%world wide diabetic patients have a risk for MASLD then have hepatic fibrosis so we study correlation Between Serum Adiponectin And Resistin Levels And Degree of Hepatic fibrosis In Metabolic dysfunction asociated steatotic liver disease in patients with type2 Diabetes Mellitus

02

Conditions studied

  • Hepatic Fibrosis
03

In context

Liver Cirrhosis

1,642 studies on the registry are indexed under Liver Cirrhosis; 358 are open to participants now.

This study's planned enrollment of 80 is below the median of 151 across 587 observational studies indexed under Liver Cirrhosis.

Browse Liver Cirrhosis studies →

Lead sponsor

Sohag University is the lead sponsor of 1,183 studies on the registry; 612 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

MASLD patients with hepatic fibrosis groupA,MASLD patients without hepatic fibrosis

Eligibility criteria

Inclusion Criteria:

  • patients of both sex who have type2 Diabetes Mellitus for less than five years

Exclusion Criteria:alcholics ,chronic liver disease elevated liver functions , sever infection

-

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
80 participants (estimated)
Patient registry
No

Groups and cohorts

  • MASLD patients with hepatic fibrosis

    MASLD with hepatic fibrosis with type 2 diabetes mellitus

    Diagnostic Test: serum Adiponectine and Resistin · Diagnostic Test: fibroscan

  • MASLD without hepatic fibrosis

    MASLD with out hepatic fibrosis with type 2 diabetes mellutis

    Diagnostic Test: serum Adiponectine and Resistin · Diagnostic Test: fibroscan

Interventions

  • Diagnostic testserum Adiponectine and Resistin

    corrolation between serum adiponectin and Resistin levels and degree of hepatic fibrosis

  • Diagnostic testfibroscan

    hepatic fibrosis detection in type 2 diabetes mellutis

06

What researchers measure

Primary outcomes

  1. degree of hepatic fibrosis in MASLD with type 2 diabetes mellitus

    adiponectineand resistine level with degree of hepatic fibrosis in MASLD pt. with type 2 DM

    Time frame: 1 year

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Chan WK, Chuah KH, Rajaram RB, Lim LL, Ratnasingam J, Vethakkan SR. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review. J Obes Metab Syndr. 2023 Sep 30;32(3):197-213. doi: 10.7570/jomes23052. Epub 2023 Sep 13. PubMed 37700494 ↗
  • Marchesini G, Vettor R, Pinzani M. MASLD emerging from the fog of fatty liver. J Hepatol. 2024 Feb;80(2):178-180. doi: 10.1016/j.jhep.2023.10.011. Epub 2023 Nov 30. No abstract available. PubMed 38278621 ↗
  • Teng ML, Ng CH, Huang DQ, Chan KE, Tan DJ, Lim WH, Yang JD, Tan E, Muthiah MD. Global incidence and prevalence of nonalcoholic fatty liver disease. Clin Mol Hepatol. 2023 Feb;29(Suppl):S32-S42. doi: 10.3350/cmh.2022.0365. Epub 2022 Dec 14. PubMed 36517002 ↗
  • Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018 Jan;67(1):123-133. doi: 10.1002/hep.29466. Epub 2017 Dec 1. PubMed 28802062 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06715189
Lead sponsor
Sohag University
Responsible party
Elzahraa Kadry Mohamed (Teaching assistant fellow At sohag teaching hospital, Sohag University) — Principal investigator
First posted
Dec 4, 2024
Start date
Dec 1, 2024 (estimated)
Primary completion
Dec 1, 2025 (estimated)
Completion
Dec 30, 2025 (estimated)
Last update
Dec 4, 2024

Study contacts

ELZAHRAA K Mohammed, spcialist
Contact
elzahraaadbelrehem@sohag.edu.eg
01064954825
usama M Abdelaal, professor
Contact
01065962094

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Liver Cirrhosis→

Other studies from this sponsor

Sohag University

Start the discussion